Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- LCI Industries names interim CEO as Jason Lippert retires
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 2, 2023 4:05 PM EDTCompany to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials
Company expanding strategic focus to autoimmune diseases and immuno-oncology
Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023
Secured new BARDA funding for the development of RNA-delivered monoclonal antibodies
$1.7 billion in cash, cash equivalents and investments as of September 30, 2023
Conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET, November 2, 2023
SAN FRANCISCO--(BUSINESS WIRE)-- Vir... More
